An observational study in Hepatitis A Vaccine and Varicella Immunisation, sponsored by Shandong University. Not yet recruiting at 1 site in China. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Shandong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hepatitis with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Hepatitis · China.
Among the 25 studies in Hepatitis with a site in China, this one is one of 2 that started in 2026, is one of 9 observational ones, and was the 25th registered.
343 studies on the registry are indexed under Hepatitis; 51 are open to participants now.
Browse Hepatitis studies →6 of the 25 studies in Hepatitis with a site in China are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in China, Australia, Japan and 4 more countries
Ages 18–65
Wuxi Hisky Medical Technology Co Ltd · Sites in China
Ages 18+
Hexaell Biotech Co., Ltd. · Sites in China
Ages 18–65
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–70 · Healthy volunteers
Minghui Li · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.
This study: 12 Months to 23 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35,000 is above the median of 358 across 90 observational studies indexed under Hepatitis.
Median enrollment 168 across the 16 interventional studies, 365 across the 9 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 25 have an industry lead sponsor. The 10 most frequent:
Shandong University is the lead sponsor of 293 studies on the registry; 61 are open to participants now.
Shandong University has 1 study filed under Hepatitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Hepatitis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn whether offering same-day co-administration of the varicella (chickenpox) vaccine and the inactivated hepatitis A vaccine at routine vaccination clinics helps children in China complete both vaccines on time, and how parents feel about this service.
The main questions it aims to answer are:
Participants will receive routine vaccination care as usual. After clinic staff explain the options - both vaccines on the same day at different injection sites, on different days, or waiting - parents freely choose, and the study records the choice. Families who take part receive short follow-up contacts about 1 week, 1 month, and 6 weeks after each vaccination to ask about fever, rash, or other health problems, complete a short satisfaction survey at 1 month, and are followed for 90 days through immunization records. Results will also be compared with de-identified immunization records of similar children from the same clinics before the service was introduced.
Children aged 12-23 months attending participating primary-level vaccination clinics in Shandong Province, China, who are due for the first dose of a live attenuated varicella vaccine and/or indicated doses of inactivated hepatitis A vaccine. Screening is consecutive on each vaccination day.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children with temporary health conditions leading to deferral on that day may enter the Deferred/Unvaccinated Group for acceptance, service process and timeliness observations, but are not included in the post-vaccination safety analysis of that episode.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children aged 12-23 months who, on the day of enrollment, are assessed by the vaccination clinician as eligible for both the first dose of a live attenuated varicella vaccine and an inactivated hepatitis A vaccine , and whose guardians voluntarily choose to receive both vaccines on the same calendar day at different injection sites. Children receive routine care including a 30-minute on-site observation period after vaccination, followed by active safety follow-up on Days 7 (+/-2), 30 (+/-5) and 42 (+/-7). Parental satisfaction is assessed at Day 30, and vaccination timeliness (completion of both vaccines, number of visits, reasons for delay) is tracked through Day 90 after screening. Co-administration of other age-appropriate vaccines (e.g., MMR, DTaP) is permitted and recorded; these children are analyzed as a prespecified subgroup.
Biological: Live Attenuated Varicella Vaccine · Biological: Inactivated Hepatitis A Vaccine
Children aged 12-23 months who are assessed as eligible for both vaccines on the same day, but whose guardians voluntarily choose to receive the varicella vaccine and the inactivated hepatitis A vaccine on different calendar days. Safety observation restarts for each administered vaccine, with an observation window of 30 days for the inactivated hepatitis A vaccine and 42 days for the live attenuated varicella vaccine, and active follow-up on Days 7, 30 and 42 after each vaccination. Completion of both vaccines, number of clinic visits, interval between doses, and reasons for delay are tracked through Day 90 after screening; parental satisfaction is assessed at Day 30. Children contribute to the overlapping exposure-based safety analysis sets according to the vaccine actually received at each visit, with the observation window restarting at each administration, so a child receiving both vaccines on separate days contributes to both sets.
Biological: Live Attenuated Varicella Vaccine · Biological: Inactivated Hepatitis A Vaccine
Children aged 12-23 months who are assessed as eligible for vaccination on the day of screening, but whose guardians voluntarily choose to defer or not receive one or both of the study vaccines on that day (including temporary deferral for health reasons). This group does not contribute to post-vaccination safety analysis. It is followed only for acceptance-related and timeliness outcomes: completion of the two vaccines, number of clinic visits, and reasons for deferral or delay are tracked through Day 90 after screening. Guardians who decline study participation still receive routine vaccination services as usual.
Live attenuated varicella vaccine (Oka strain), given as a single 0.5 mL subcutaneous dose according to the national immunization schedule and the vaccine label. In this non-interventional study the vaccine is administered as routine care; the study does not assign, modify, or delay any vaccination. This is the exposure of interest for the 0-42 day safety observation window, including delayed varicella-like rash.
Inactivated hepatitis A vaccine, given intramuscularly in the upper arm according to the national immunization schedule and the vaccine label. In this non-interventional study the vaccine is administered as routine care; the study does not assign, modify, or delay any vaccination. This is the exposure of interest for the 0-30 day safety observation window.
Acceptance rate of same-day co-administration
Proportion of children eligible for both vaccines on the same day whose guardians choose same-day co-administration of the varicella vaccine and the inactivated hepatitis A vaccine. Denominator: children in the core analysis set (assessed eligible for both vaccines on the enrollment day). Reported as a percentage with 95% confidence interval.
Time frame: Day 0 (at enrollment, i.e., the day of the vaccination decision)
Completion rate of both vaccines within 90 days
Proportion of children in the core analysis set who complete the study-relevant (due) doses of both the varicella vaccine and the inactivated hepatitis A vaccine within 90 days after screening. "Due doses" means the doses indicated at that visit and does not require completion of the full two-dose hepatitis A primary series within 90 days. Completion is verified through the immunization information system or guardians' vaccination records. Reported as a percentage with 95% confidence interval. This endpoint evaluates service delivery and short-term completion; the 90-day window is not a vaccine safety observation window.
Time frame: Through 90 days after screening
Single-visit completion rate
Proportion of children who complete all indicated study vaccines on the day of the first eligible visit. Denominator: children eligible for vaccination on that day. Reported as a percentage with 95% confidence interval.
Time frame: Day 0
Parental satisfaction score
Guardian-reported satisfaction assessed with service-evaluation items covering clarity of pre-vaccination information, adequacy of explanation of the co-administration options, convenience of scheduling and on-site procedures, waiting time, staff communication and overall satisfaction, using 5-point Likert scales; the proportion willing to recommend the service to other parents is also reported. Analysis population: guardians of children in the core analysis set.
Time frame: Day 30 (+/-5) after screening/enrollment visit (S0); for children vaccinated at later visits, the schedule and unified anchor are specified in the study operations manual
Delayed or incomplete vaccination and number of clinic visits
Proportion of children with delayed or incomplete vaccination beyond the recommended age window or within 90 days after screening, and the mean/median number of clinic visits required to complete both vaccines, compared between the post-implementation cohort and the historical control (pre-implementation) cohort using chi-square tests, rank-sum tests and multivariable adjustment or propensity score methods where appropriate.
Time frame: Through 90 days after screening
Incidence of solicited adverse events within 7 days after vaccination
Incidence of solicited local reactions (pain/tenderness, erythema, swelling, induration, rash, itching) and systemic reactions (fever, acute allergic manifestations, diarrhea, nausea, vomiting, decreased appetite, abnormal crying, decreased activity) within 0-7 days after vaccination, collected by active follow-up on Day 7 (+/-2). Analyzed descriptively by vaccine exposure (same-day vs separate-day administration) with 95% confidence intervals.
Time frame: 0-7 days after vaccination
Incidence of adverse events within 30 days after hepatitis A vaccination
Incidence of adverse events (AE) and serious adverse events (SAE) within 0-30 days after administration of the inactivated hepatitis A vaccine, including suspected adverse events following immunization (AEFI). Collected by 30-minute on-site observation, active follow-up on Days 7, 30 (+/-5) and 42 (+/-7), medical records review, and linkage to the national AEFI surveillance system. Analysis population: all doses of inactivated hepatitis A vaccine actually administered to study children, regardless of enrollment group (hepatitis A exposure analysis set); the observation window restarts at each administration, each dose contributes one 30-day observation, and the hepatitis A and varicella exposure sets overlap and are therefore not additive. Reported as percentages with 95% confidence intervals.
Time frame: 0-30 days after hepatitis A vaccination
Incidence of adverse events within 42 days after varicella vaccination
Incidence of AE and SAE within 0-42 days after administration of the live attenuated varicella vaccine, with particular attention to delayed varicella-like rashes and fever, including AEFI. Collected by 30-minute on-site observation, active follow-up on Days 7, 30 (+/-5) and 42 (+/-7), medical records review, and linkage to the national AEFI surveillance system. Analysis population: all doses of live attenuated varicella vaccine actually administered to study children, regardless of enrollment group (varicella exposure analysis set); the observation window restarts at each administration, each dose contributes one 42-day observation, and the varicella and hepatitis A exposure sets overlap and are therefore not additive. Reported as percentages with 95% confidence intervals.
Time frame: 0-42 days after varicella vaccination
Plan to share: Yes — De-identified individual participant data that underlie the results reported in this article will be made available, beginning 3 months and ending 5 years following article publication. Data will be shared with investigators whose proposed use of the data has been approved by an independent review committee. Proposals should be directed to the corresponding author.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 3 months and ending 5 years following the publication of the main study results.
Access criteria: Researchers who provide a methodologically sound proposal and have obtained approval from an independent review committee. Data will be shared upon execution of a data use agreement. Proposals should be directed to the corresponding author.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.
Of 36 observational studies under Hepatitis, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 195. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.